October 28, 2019

IntegriChain Named to Philadelphia100 List of Fastest Growing Private Companies

Rapid Expansion of Leading Life Sciences Data and Analytics SaaS Company Places Organization in Top-30

Philadelphia, PA, October 28, 2019– IntegriChain, a leading life sciences commercial data and analytics company that helps patients start therapy faster and stay on therapy longer, today announced that the Company has been named to the Philadelphia100 list of fastest growing, privately held entrepreneurial companies. IntegriChain placed 29th on the Philadelphia100 list in an awards ceremony last week.

“We are proud to be named to the Philadelphia100 list and share this recognition with our entire team of outstanding data scientists and professionals who work tirelessly every day to realize our mission to save patient days of therapy,” said IntegriChain CEO Kevin Leininger. “We have rapidly grown over the last three years through the organic buildout of our SaaS platform as well as through strategic acquisitions, and today we serve the data and analytics needs of more than 175 leading Life Sciences manufacturers – from Big Pharma to emerging innovators. We have built a world-class platform for the Life Sciences industry right here in Center City, and we are honored to be part of Greater Philadelphia’s business and data tech communities.”

The Philadelphia100® has been the hallmark of entrepreneurial achievement in the region since 1988. Cofounded by the Entrepreneurs’ Forum of Greater Philadelphia to celebrate the success of both its CEO members and local CEOs, the Philadelphia100® awards identifies and honors the 100 fastest growing, privately held entrepreneurial companies in the Greater Philadelphia Region. What started as an idea to bring recognition to our region has emerged as a new standard – a standard of excellence. The Philadelphia100 is a merit-based program.

Only companies that are among the fastest growing, privately held companies are awarded the Philadelphia10 designation. The integrity of the process and the resulting list makes the Philadelphia100® one of the most sought-after awards in the region. The Philadelphia100 winners are celebrated at an awards program among 500 leaders and acknowledged in a special section of the Philadelphia Inquirer reaching nearly 1 million readers.

About IntegriChain
IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Our mission is to help all stakeholders in pharmaceutical access save as many patient days of therapy as possible. Our data-science-driven ICyte Platform and solutions uniquely focus on access challenges after the patient and provider commit to therapy. More than 165 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Somerset, NJ, and Pune, India. For more information, visit and our blog, or follow us on Twitter @IntegriChain and LinkedIn.

Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 |


adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article